FHL1抗体

+ +

•  

   

     Gel: 8%SDS-PAGE, Lysate: 40 μg, Lane 1-3: Human adrenal pheochromocytoma tissue, Human fetal muscle tissue, Human skeletal muscle tissue, Primary antibody: P08334(FHL1 Antibody) at dilution 1/500, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 5 seconds    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human colon cancer tissue using P08334(FHL1 Antibody) at dilution 1/20. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human liver cancer tissue using P08334(FHL1 Antibody) at dilution 1/20. (Original magnification: ×200)    

  
  

**Background of FHL1 Antibody**

FHL1 (Four and a Half LIM Domain 1) is a member of the LIM-only protein family, characterized by four LIM domains and a half LIM motif. These domains mediate protein-protein interactions, enabling FHL1 to participate in diverse cellular processes, including cytoskeletal organization, signal transduction, and transcriptional regulation. Primarily expressed in skeletal and cardiac muscles, FHL1 plays critical roles in muscle development, mechanotransduction, and stress response.

FHL1 antibodies are essential tools for studying its expression, localization, and function. They are widely used in research applications such as Western blotting, immunohistochemistry, and immunofluorescence to detect FHL1 in tissues or cell lines. Mutations in the *FHL1* gene are linked to several human disorders, including X-linked myopathies (e.g., reducing body myopathy), Emery-Dreifuss muscular dystrophy, and cardiac conditions like hypertrophic cardiomyopathy. FHL1 antibodies aid in diagnosing these conditions by identifying abnormal protein expression or aggregation in patient samples.

Additionally, FHL1 has been implicated in cancer progression, with studies suggesting its dual role as a tumor suppressor or promoter depending on context. Antibodies against FHL1 help explore these mechanisms, enabling insights into disease pathways. Commercial FHL1 antibodies are available from various suppliers, often validated for specificity across species. However, variability in isoforms (FHL1A, B, C) necessitates careful antibody selection to ensure target specificity. Ongoing research continues to uncover FHL1's multifaceted roles, underscoring the importance of reliable antibodies in both basic and clinical studies.